The collaboration could improve reliability and consistency of temperature-sensitive transportation
Atelerix, a cell preservation and biological transport specialist has partnered with biotechnology organ-on-chip company Cherry Biotech to integrate non-cryogenic transport solutions with advanced organoid models.
“This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix’s solutions,” said Atelerix CEO Alastair Carrington.
“It is fantastic to work alongside such an innovative CRO, we are delighted that our preservation technology has already proven itself in delivering organoid models reliably and hassle-free to researchers worldwide.”
The aim is to improve the reliability and consistency of transporting temperature-sensitive materials without the complications of cold-chain logistics.
Atelerix’s hydrogel technology will also be validated for the stable shipment of Cherry Biotech’s organoidPlate, a multi-well plate with ready-to-use organoids for adipose tissue, breast cancer, liver and lung.
“The hydrogel preservation technology maintains cell viability for days at room temperature, removing cold-chain constraints and reducing environmental footprint,” said Cherry Biotech chief business development officer Pierre Gaudriault.
Atelerix’s hydrogel technology will be combined with Cherry Biotech’s advanced 3D organoid models to facilitate global extended-duration shipment during an initial 12-month trial period.
Cherry Biotech’s in vitro product range combine AI analysis, high-resolution live imaging and precisely controlled organoid culture to better predict the efficacy and safety of drugs, generating real life-like preclinical data.
